Second-generation antihistamines: a comparative review.

Abstract:

:Second-generation histamine H1 receptor antagonists (antihistamines) have been developed to reduce or eliminate the sedation and anticholinergic adverse effects that occur with older H1 receptor antagonists. This article evaluates second-generation antihistamines, including acrivastine, astemizole, azelastine, cetirizine, ebastine, fexofenadine, ketotifen, loratadine, mizolastine and terfenadine, for significant features that affect choice. In addition to their primary mechanism of antagonising histamine at the H1 receptor, these agents may act on other mediators of the allergic reaction. However, the clinical significance of activity beyond that mediated by histamine H1 receptor antagonism has yet to be demonstrated. Most of the agents reviewed are metabolised by the liver to active metabolites that play a significant role in their effect. Conditions that result in accumulation of astemizole, ebastine and terfenadine may prolong the QT interval and result in torsade de pointes. The remaining agents reviewed do not appear to have this risk. For allergic rhinitis, all agents are effective and the choice should be based on other factors. For urticaria, cetirizine and mizolastine demonstrate superior suppression of wheal and flare at the dosages recommended by the manufacturer. For atopic dermatitis, as adjunctive therapy to reduce pruritus, cetirizine, ketotifen and loratadine demonstrate efficacy. Although current evidence does not suggest a primary role for these agents in the management of asthma, it does support their use for asthmatic patients when there is coexisting allergic rhinitis, dermatitis or urticaria.

journal_name

Drugs

journal_title

Drugs

authors

Slater JW,Zechnich AD,Haxby DG

doi

10.2165/00003495-199957010-00004

subject

Has Abstract

pub_date

1999-01-01 00:00:00

pages

31-47

issue

1

eissn

0012-6667

issn

1179-1950

journal_volume

57

pub_type

杂志文章,meta分析

相关文献

DRUGS文献大全
  • Quinolone activity against anaerobes: microbiological aspects.

    abstract::Currently available quinolones are either inactive or marginally active against anaerobic bacteria. This review summarises the in vitro activity of currently available as well as experimental quinolones against clinically significant anaerobic bacteria. Quinolones with low activity against anaerobes include ciprofloxa...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199500492-00012

    authors: Appelbaum PC

    更新日期:1995-01-01 00:00:00

  • Acitretin : A Review of its Pharmacology and Therapeutic Use.

    abstract:SYNOPSIS:Acitretin (etretin), a second generation monoaromatic retinoid for use in the treatment of severe psoriasis and other dermatoses, is the major active metabolite of etretinate and possesses a similar therapeutic index; i.e. a similar ratio of clinical efficacy to adverse effects. When used alone at a maintenanc...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-199243040-00010

    authors: Pilkington T,Brogden RN

    更新日期:1992-04-01 00:00:00

  • Assessment of the risk-benefit ratio for antiarrhythmic drug use.

    abstract::Arrhythmia treatment has always been difficult, particularly as there are no good indicators of the optimal management strategy. The introduction of new antiarrhythmic agents has forced reappraisal of how these drugs are used. Dynamic electrocardiography and invasive electrophysiological studies are important tools fo...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198836050-00005

    authors: Campbell RW

    更新日期:1988-11-01 00:00:00

  • Acitretin. A review of its pharmacology and therapeutic use.

    abstract::Acitretin (etretin), a second generation monoaromatic retinoid for use in the treatment of severe psoriasis and other dermatoses, is the major active metabolite of etretinate and possesses a similar therapeutic index; i.e. a similar ratio of clinical efficacy to adverse effects. When used alone at a maintenance dosage...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199243040-00010

    authors: Pilkington T,Brogden RN

    更新日期:1992-04-01 00:00:00

  • Idiopathic membranous nephropathy: management strategies.

    abstract::Treatment of idiopathic membranous nephropathy is based on a 'symptomatic' therapy that includes ACE inhibitors or angiotensin II receptor antagonists, and on an 'aetiological' therapy aimed at modulating underlying immunological mechanisms. The role of the latter is still debated given the usually indolent course of ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200969100-00002

    authors: Quaglia M,Stratta P

    更新日期:2009-07-09 00:00:00

  • Effects of ketanserin tartrate on serum lipids in patients with essential hypertension.

    abstract::Several antihypertensive agents such as thiazide diuretics and some beta-blockers have recently been shown to adversely affect lipid metabolism. Moreover, there is a growing suspicion that the adverse effect on plasma lipids might outweigh the favourable effect of lowering blood pressure. The effect of ketanserin tart...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章

    doi:10.2165/00003495-198800361-00006

    authors: Nakamura H,Hirata F,Yasugi T,Mizuno M,Saito E,Ishikawa T,Tada N,Nakaya N,Homma Y,Takeuchi I

    更新日期:1988-01-01 00:00:00

  • A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee.

    abstract:UNLABELLED:Joint pain is the main complaint in patients affected by osteoarthritis (OA), and NSAIDs are commonly used to treat pain associated with OA. Over the past few years, cyclo-oxygenase (COX)-2-selective inhibitors have been proved to have certain advantages over non-selective NSAIDs and have been increasingly u...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-200363001-00006

    authors: Bianchi M,Broggini M

    更新日期:2003-01-01 00:00:00

  • Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures.

    abstract::Iloprost is an analogue of epoprostenol (prostacyclin; PGI2; a potent but short-lived prostanoid mainly produced in the vascular endothelium) and mimics the pharmacodynamic properties of this compound, namely: inhibition of platelet aggregation, vasodilatation and, as yet ill-defined, cytoprotection. Improved metaboli...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199243060-00008

    authors: Grant SM,Goa KL

    更新日期:1992-06-01 00:00:00

  • Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection.

    abstract::Stavudine is a nucleoside analogue which undergoes intracellular phosphorylation to its active metabolite, stavudine-5'-triphosphate. At clinically relevant concentrations, the active metabolite restricts HIV replication by inhibiting the inclusion of thymidine-5'-triphosphate into proviral DNA by HIV reverse transcri...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199651050-00009

    authors: Lea AP,Faulds D

    更新日期:1996-05-01 00:00:00

  • Meloxicam.

    abstract::Meloxicam is a new nonsteroidal anti-inflammatory drug (NSAID) developed for the treatment of rheumatoid arthritis and osteoarthritis. It has greater in vitro and in vivo inhibitory action against the inducible isoform of cyclo-oxygenase (COX-2), which is implicated in the inflammatory response, than against the const...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199651030-00007

    authors: Noble S,Balfour JA

    更新日期:1996-03-01 00:00:00

  • Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events.

    abstract::The prevalence of use of long-term systemic glucocorticoid therapy in the general adult population is 1 %. This figure increases to up to 3 % in elderly women. Metabolic (i.e. diabetes mellitus, dyslipidemia, weight gain, lipodystrophy) and cardiovascular (i.e. hypertension, cardiovascular events) adverse events are c...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-014-0282-9

    authors: Fardet L,Fève B

    更新日期:2014-10-01 00:00:00

  • Optimizing the use of thrombolytics in ST-segment elevation myocardial infarction.

    abstract::The advent of thrombolytic therapy was a major advance in the treatment of ST-segment elevation myocardial infarction (STEMI). The administration of fibrinolytic reperfusion therapy can reduce mortality rates by as much as 30%, with the greatest benefit observed if therapy is administered soon after symptom onset. Out...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11317670-000000000-00000

    authors: Morse MA,Todd JW,Stouffer GA

    更新日期:2009-10-01 00:00:00

  • Pharmacokinetics of cefoperazone: a review.

    abstract::The pharmacokinetics of cefoperazone in normal subjects, and in patients with hepatic and renal dysfunction are reviewed. After intravenous administration of 2 g of cefoperazone, levels in serum ranged from 202 to 375 microgram/ml depending on the period of drug administration. After intramuscular injection of 2 g of ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198100221-00010

    authors: Craig WA,Gerber AU

    更新日期:1981-01-01 00:00:00

  • Correction to: Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections.

    abstract::The original article can be found online. ...

    journal_title:Drugs

    pub_type: 已发布勘误

    doi:10.1007/s40265-020-01407-8

    authors: Scott LJ

    更新日期:2020-09-01 00:00:00

  • Treatment of the chronic fatigue syndrome. A review and practical guide.

    abstract::The chronic fatigue syndrome (CFS) was formally defined in 1988 to describe a syndrome of severe and disabling fatigue of uncertain aetiology associated with a variable number of somatic and/or psychological symptoms. CFS has been reported in most industrialised countries and is most prevalent in women aged between 20...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199346040-00005

    authors: Blondel-Hill E,Shafran SD

    更新日期:1993-10-01 00:00:00

  • Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis.

    abstract::Echinocandins are a new class of antifungal agents with a novel mechanism of action (interference with fungal cell wall synthesis). Caspofungin (Cancidas), Caspofungin MSD) is the first echinocandin to be approved and is administered intravenously. Caspofungin 50 mg/day had similar efficacy to intravenous fluconazole ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200363200-00008

    authors: Keating G,Figgitt D

    更新日期:2003-01-01 00:00:00

  • ZD1839 ('Iressa') as an anticancer agent.

    abstract::ZD1839 ('Iressa') is an orally active, selective epidermal growth factor receptor-tyrosine kinase inhibitor which blocks signal transduction pathways implicated in the proliferation and survival of cancer cells and other host-dependent processes promoting cancer growth. In preclinical studies, ZD1839 produced reversib...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200060001-00004

    authors: Baselga J,Averbuch SD

    更新日期:2000-01-01 00:00:00

  • Protective effects of calcium antagonists against ischaemia and reperfusion damage.

    abstract::The most positive results in this area have been those of the second Danish Study Group on Verapamil in Myocardial Infarction (1990) which assessed the benefit of treatment with verapamil from the second week after myocardial infarction. Verapamil produced a significant reduction in both mortality and reinfarction rat...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199100421-00005

    authors: Ferrari R,Visioli O

    更新日期:1991-01-01 00:00:00

  • New and Emerging Therapies for Alopecia Areata.

    abstract::Alopecia areata (AA) is an autoimmune condition that affects up to 2% of the general population. Currently available treatment options for AA are of limited efficacy and can be associated with adverse effects. The advancement in understanding of the genetic and molecular mechanisms of AA has led to the development of ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01293-0

    authors: Pourang A,Mesinkovska NA

    更新日期:2020-05-01 00:00:00

  • Managing cancer-related anorexia/cachexia.

    abstract::Cancer-related anorexia/cachexia (CAC) is a complex phenomenon in which metabolic abnormalities, proinflammatory cytokines produced by the host immune system, circulating tumour-derived catabolic factors, decreased food intake, and probably additional unknown factors, all play different roles. This review examines the...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161040-00004

    authors: Mantovani G,Macciò A,Massa E,Madeddu C

    更新日期:2001-01-01 00:00:00

  • Treatment of Kaposi's sarcoma. Current guidelines and future perspectives.

    abstract::Kaposi's sarcoma is the most common malignancy associated with HIV infection, and the morbidity and mortality attributable to AIDS-related Kaposi's sarcoma (AIDS-KS) may be increasing. No curative therapy is available for AIDS-KS, but palliative therapy can eliminate or reduce cosmetically unacceptable lesions, reduce...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199448040-00006

    authors: Northfelt DW

    更新日期:1994-10-01 00:00:00

  • Antirheumatic drugs: clinical pharmacological and therapeutic aspects.

    abstract::There are many current concepts of the pathogenesis of rheumatic diseases which incorporate immunological, infectious and hereditary factors. Rheumatic diseases may sometimes become apparent after trauma, be associated with certain diseases and may be induced by nerve damage and serum sickness. Systemic lupuserythemat...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-197510050-00008

    authors: Smyth CJ,Bravo JF

    更新日期:1975-01-01 00:00:00

  • Effects of enalapril on clinical status, biochemistry, exercise performance and haemodynamics in heart failure.

    abstract::The effects of enalapril on clinical well-being, treadmill exercise performance, haemodynamic measurements, hormone levels, and plasma biochemistry in patients with moderate heart failure, were assessed in a 12-week placebo-controlled, double-blind study. Maintenance frusemide and digoxin treatment was continued throu...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章

    doi:10.2165/00003495-198500301-00011

    authors: Webster MW,Fitzpatrick MA,Hamilton EJ,Nicholls MG,Ikram H,Espiner EA,Wells JE

    更新日期:1985-01-01 00:00:00

  • Antiarrhythmic therapies for the prevention of sudden cardiac death.

    abstract::Despite remarkable advances in cardiovascular therapeutics, sudden cardiac death remains a significant problem. In this review, data from clinical trials and other studies on antiarrhythmic therapies have been evaluated in order to determine effective strategies for the prevention of sudden cardiac death in high risk ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199754020-00003

    authors: McAlister FA,Teo KK

    更新日期:1997-08-01 00:00:00

  • Effects of alpha-adrenoceptor blockers on renal function and blood pressure adjustment in human hypertension.

    abstract::In this paper the different aspects of the role played by alpha-adrenoceptors in the control of renin secretion from the juxtaglomerular apparatus and renal sodium and water reabsorption, and the effects of alpha-adrenoceptor antagonists on systemic haemodynamics, will be investigated. Animal experiments suggest that ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198800356-00007

    authors: Leonetti G

    更新日期:1988-01-01 00:00:00

  • Damoctocog Alfa Pegol: A Review in Haemophilia A.

    abstract::Damoctocog alfa pegol (Jivi®) is approved in the USA, EU, Japan and Canada for the treatment and prophylaxis of previously treated patients aged ≥ 12 years with haemophilia A. Formulated with a 60 kDa polyethylene glycol (PEG) moiety, damoctocog alfa pegol is an intravenously (IV) administered recombinant factor VIII ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01152-7

    authors: Paik J,Deeks ED

    更新日期:2019-07-01 00:00:00

  • Prediction of response to cancer chemotherapy.

    abstract::Cytotoxic chemotherapy plays a key role in the treatment of carcinoma for thousands of patients annually who either present with metastatic disease or relapse after surgical excision of apparently localised disease. Unfortunately, there is such a wide range of responsiveness to drug therapy within individual tumour ty...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198326050-00004

    authors: Sarosdy MF,Von Hoff DD

    更新日期:1983-11-01 00:00:00

  • Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis.

    abstract::Alemtuzumab (Lemtrada®) is an anti-CD52 monoclonal antibody approved in the EU for the treatment of highly active relapsing-remitting multiple sclerosis (RRMS). In phase 3 trials in patients with active RRMS, intravenous alemtuzumab was more effective than subcutaneous interferon β-1a in terms of decreasing relapse ra...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01437-2

    authors: Syed YY

    更新日期:2021-01-01 00:00:00

  • Insulin glargine: an updated review of its use in the management of diabetes mellitus.

    abstract::Insulin glargine is a human insulin analogue prepared by recombinant DNA technology. Modification of the human insulin molecule at position A21 and at the C-terminus of the B-chain results in the formation of a stable compound that is soluble at pH 4.0, but forms amorphous microprecipitates in subcutaneous tissue from...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验,评审

    doi:10.2165/00003495-200363160-00007

    authors: Dunn CJ,Plosker GL,Keating GM,McKeage K,Scott LJ

    更新日期:2003-01-01 00:00:00

  • Cisatracurium besilate. A review of its pharmacology and clinical potential in anaesthetic practice.

    abstract::Cisatracurium besilate (besylate) is a nondepolarising neuromuscular blocking agent with an intermediate duration of action. It is the R-cis, R'-cis isomer of atracurium besilate and is approximately 3-fold more potent than the mixture of isomers that constitute the parent drug. The ED95 for cisatracurium besilate (do...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199753050-00012

    authors: Bryson HM,Faulds D

    更新日期:1997-05-01 00:00:00